A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
← catalyst calendarSponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
54actual
Sites
13
Countries
Australia, Canada, Israel +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-08-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alexander Disease
Interventions
- Drug: zilganersen — also filed as ION373
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in the 10-Meter Walk Test (10MWT)
measured Baseline and Week 61
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed